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Essential Tremor: A Review
Essential tremor (ET) is one of the most prevalent movement disorders globally:
approximately 1% of the population is affected (Haubenberger & Hallet, 2018). In the past, ET
has been grossly oversimplified clinically and pathologically and only through recent study has
the complexity of the disease process and presentation been made apparent. Despite the recent
advances in research regarding ET, the general public is still largely unfamiliar with the various
aspects of the disease (Cristal et al., 2018). Perhaps even more surprising is the similar lack of
knowledge that ET patients have regarding their own disease (Cristal et al., 2018). Recent
literature on ET demonstrates an increased prevalence of previously unassociated non-motor
symptoms such as depression, anxiety, apathy, dementia, and auditory deficits. These aspects of
ETremain unknown among ET patients, despite their substantial effects on quality of life.
Knowledge deficiencies such as these must be addressed in both clinicians and patients so as to
improve the quality of life for ET patients. The following paper aims to educate the reader on the
presentation, pathophysiology, progression, etiology, and treatment of ET.

Symptoms
Historically, ET has been regarded as a monosymptomatic disorder (Ashenhurst, 1973).
However, recent research has demonstrated the elaborate nature of its different manifestations.
Current literature on ET notes a variety of motor and nonmotor symptoms including tremors of
the extremities, voice, head, as well as an increased prevalence of cognitive and psychiatric
issues such as dementia, anxiety, and depression. While the prevalence of each co-symptom
varies, the defining characteristic of ET remains an upper extremity tremor (Ashenhurst, 1973).
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Motor
Upper extremity tremor.
The predominant clinical exhibition in ET patients is a kinetic tremor of the upper
extremities (Brennan, Jurewicz, Ford, Pullman, & Louis, 2002). Kinetic tremor may occur with
multiple voluntary movements such as eating, drinking, writing, and many other activities of
daily living (Louis, 2005). A postural tremor of the arms is another common component of ET;
however, it typically demonstrates a lower severity relative to kinetic tremor (Brennan et al.,
2002). Deuschl, Raethjen, Hellriegel, and Elble (2000) suggests that intention tremor should be
included in the clinical definition of ET in conjunction with postural tremor, despite similar
clinical presentations. Cohen, Pullman, Jurewicz, Watner, and Louis (2003) and Rajput,
Rozdilsky, Ang, and Rajput (1993) provide evidence for rest tremor, distinct from Parkinson’s
Disease, in 20-33% of ET patients. While the significance of rest tremor in ET is still unknown,
its presence in ET cases is associated with increased severity and longer duration of other ET
symptoms (Cohen et al., 2003). Hubble, Busenbark, Pahwa, Lyons, and Koller (1997)
demonstrated that men with ET often present with an increased severity of postural hand tremor;
women with ET demonstrated a greater prevalence (>60%) of head and voice tremor than men
(~30%). The differentiation of symptom variance between sexes is important for accurate clinical
diagnosis; thus the differences noted in men and women regarding the prevalence of ET
symptoms are noteworthy.
Additional tremor loci.
Although ET primarily exhibits symptoms in the arms, it may also manifest as a tremor
of the head, voice, trunk, legs, and other facial musculature as noted by Critchley (1949).
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Prevalence of dual head (neck) and arm tremor among ET cases tends to fall between 34-53%
depending on the study sample (Louis, 2005), while isolated head tremor occurs in less than 10%
of ET cases (Louis, Ford, & Frucht, 2003). Approximately 75% of head tremor cases take the
form of a “no-no” variety (Bain et al., 1994). Tandem gait abnormalities have also been noted in
50% of ET patients aged >70 years with a 2-fold increase in risk of abnormal gait development
as compared to a healthy elderly population (Singer, Sanchez-Ramos, & Weiner, 1994). The
extensive, inconsistent nature of ET motor symptoms is only further complicated by the variety
of non-motor symptoms that may be present as well.
Non-motor
Auditory and olfactory.
An association between ET and auditory and olfactory deficits has been demonstrated
(Sengul, 2020). Hearing loss and neurodegenerative disease processes often go hand in hand.
Two studies have reported significant association between ET and hearing impairment as well as
an increased prevalence of impairment in ET as compared to other neurodegenerative conditions
such as Parkinson’s Disease (Ghika, Kyrozis, Potagas, & Louis, 2015; Sengul, 2020). While
these discoveries are helpful, further research must be completed to illuminate the nature of this
association. Reports regarding a positive relationship between olfactory deficits and ET are
conflicting, primarily demonstrating that further research must be accomplished prior to the
development of any concrete assumptions (Louis, 2016).
Cognitive and psychiatric.
An increased prevalence of several cognitive and psychiatric features have been noted
among ET patients as well (Louis, 2016). ET patients have demonstrated mild cognitive
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impairment greater than age-matched controls (Lacritz, Dewey, Giller, & Cullum, 2002). This
impairment primarily involves executive function and memory and appears to be progressive
(Louis, 2016). An increased prevalence of dementia has also been noted among ET cases
(Janicki, Cosentino, & Louis, 2013). ET patients also demonstrate a greater amount of depressive
symptoms than controls (Louis, 2016). Dogu, Louis, Sevim, Kaleagasi, & Aral (2005)
demonstrated that increased depression scores correlated with an increase in tremor severity
among ET patients. Within ET patients, those with a head tremor demonstrate a higher
prevalence of depression and memory deficiencies (Peng et al., 2020).
There is a dearth of research regarding the presence of apathy in ET patients. However,
one study noted an increase in apathy among non-depressed ET cases as compared to controls
(Louis, Huey, Gerbin, & Viner, 2012). This is notable due to the increased presence of apathy
noted among other movement disorders such as Parkinson’s Disease (35%) (Santangelo et al.,
2013). Despite the poorly documented nature of apathy in ET, multiple studies have reported a
substantially increased incidence of anxiety among ET patients (Sengul et al., 2014; Chandran et
al., 2012) paired with an increased acuity of anxiety as compared to controls (Dogu et al., 2005).
ET patients have specifically demonstrated a higher rate of social phobia compared to controls
(Schneier, Barnes, Albert, & Louis, 2001). The prevalence of anxiety among ET patients was
shown to still be greater even in patients with mild ET who had not been previously diagnosed
(Dogu et al., 2005). This is noteworthy because it demonstrates an increased prevalence of
anxiety that is not developed in response to diagnosis or severe symptoms, but appears to be tied
directly to the disease process itself.
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Alexithymia—the inability to identify and describe experienced emotions—has recently
been demonstrated to appear at significantly higher rates in ET patients than controls, even
independent of depressive symptoms (Sengul et al., 2020). While further research must be
performed to further demonstrate the clinical applicability of this study, alexithymia has been
noted to appear with increased prevalence in Parkinson’s Disease and thus it is not particularly
surprising that it is prevalent in ET given the many similarities between the two diseases
(Assogna et al., 2012). ET patients may also demonstrate an impaired quality of sleep
(Jimenez-Jimenez, Alonso-Navarro, Garcia-Martin, & Agundez, 2020; Peng et al., 2020);
however, Sengul et al., (2014) noted that sleep deficits in ET were associated with elevated
anxiety levels and were therefore a better marker of anxiety incidence in ET than a purely
unrelated sleep impairment.
Elbelkemy, Shalash, Mansour, Hamed, and Abdelalim (2020) argued that as non-motor
symptoms in ET are increasingly evident, they should be included in the clinical definition of
ET. However, it is as yet unclear whether these non-motor symptoms are a significant part of the
primary disease process, or whether they are primarily secondary reactive symptoms of ET
(Jhunjhunwala & Pal, 2014). While this distinction is currently unclear, it is quite apparent that
ET patients exhibit a high frequency of neuropsychiatric deficits and experience a lower quality
of life due to these deficits (Lorenz, Poremba, Papengut, Schreiber, & Deuschl, 2011; Mussachio
et al., 2016 ). Therefore, clinicians should anticipate, educate, and treat ET patients for
non-motor symptoms so as to ensure a higher quality of life. Interestingly, non-motor symptoms
appear to be independent of tremor severity, further supporting their inclusion as a primary ET
component rather than a reactive component (Louis et al., 2001; Mussachio et al., 2016). The
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increasingly realized prevalence and severity of non-motor symptoms in ET further potentiates
the inclusion of non-motor symptoms as a primary disease process of what was once thought to
be a monosymptomatic tremor disorder.

Pathophysiology
The pathophysiology of ET is likely multifactorial and is not fully understood. Research
has only further demonstrated the intricacy of the disease pathology and the necessity for further
investigation on the topic. The post-mortem nature of ET biological research constitutes a
primary barrier to the attainment of concrete evidence surrounding its cause. However, the
subject has received increasing attention over the past 15 years and much has been gained
regarding the pathophysiology of ET. Currently, ET pathology is largely considered to be a
primary neurodegenerative disorder of the cerebellar cortex (Bares, Husarova, & Lungu, 2001;
Cerasa & Quattrone, 2016; Louis, 2014).
Purkinje Cell Degeneration
One theory regarding the pathophysiology of essential tremor suggests that it is due to a
progressive degeneration of Purkinje neurons (Grimaldi & Manto, 2013) of the cerebellum. In
ET patients, Purkinje cell production of Gamma-aminobutyric acid (GABA) subsequently
decreases along with the inhibitory effect on cerebellar nuclei for which GABA is produced
(Grimaldi & Manto, 2013). The Purkinje cells in ET undergo a certain degree of degeneration
which includes the development of axonal swelling (torpedoes) and reduction in dendritic cell
complexity (Louis, 2014). This reduction in dendritic arborization is thought to precede cell
death which may explain the lower Purkinje cell counts noted in ET (Ferrer, Fabregues, Pineda,
Gracia, & Ribalta, 1984; Grimaldi & Manto, 2013). Louis et al. (2014) demonstrated that with an
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increased exhibition of tremor severity, a decrease in dendritic arborization was also present; this
association provides further evidence for the direct role of Purkinje cell degeneration in
exhibition of ET symptoms.
Lin et al. (2014) established that a decrease in climbing fibre-Purkinje synapse
connection was evident in ET cases. Basket cells adjacent to Purkinje cells have also
demonstrated some extent of remodeling, further exemplifying the involvement of neighboring
processes. (Louis, 2014). Multiple Purkinje axonal irregularities—torpedoes, axonal atrophy,
increased collateralization, branching, and sprouting—are markedly increased in ET cases as
opposed to controls (Babij et al., 2013). Prior research has demonstrated that these Purkinje cell
abnormalities are compensatory in nature and a result of physiologic stress (Ramon y Cajal,
1928); these compensations would thus attempt to sustain connections despite the stress induced
by ET (Babij et al., 2013). Choe et al. (2016) suggest that the degeneration of Purkinje cells and
neighboring processes is likely due to an unknown molecular abnormality in ET patients which
could simply label Purkinje cell deviations as biomarkers resulting from a deeper cellular
pathology. Overall, it is still unclear whether Purkinje cell aberrations noted are a result of
essential tremor or simply indicate a greater predisposition to tremor development.
Louis (2014) proposed a model of cerebellar degeneration in ET. This model suggests
that an underlying molecular event of unknown origin results in Purkinje axonal remodeling,
selective cell death, adjacent processes remodeling, aberrant synapse formation, and an overall
abnormal Purkinje cell and corticofugal output (Louis, 2014). This cascading process details the
potential regenerative and degenerative modifications that occur in Purkinje cell-connected
populations, largely resulting in a rewiring of the cerebellar circuitry. A model such as this
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suggests that the neurodegenerative nature of ET elicits a modification of cerebellar circuitry and
thus the symptoms of ET begin. Despite the substantial quantity of evidence regarding Purkinje
cell abnormalities and loss, there is contradicting research that reports no difference in Purkinje
cell loss between ET cases and controls (Rajput, Robinson, Rajput, Robinson, & Rajput, 2012).
This only further exemplifies the need for further research to clarify the relationship between
Purkinje cells and ET. Overall, it is likely that the aberrations noted in Purkinje cells and their
neighboring processes play a significant role in the pathology of ET due to the considerable data
presented in the previously mentioned studies.
GABA Receptor Reduction
The GABAergic nature of Purkinje cells and their involvement in ET pathology provides
insight into the essential query of an isolated study regarding the reduction of GABA receptors in
ET. Paris-Robidas et al. (2012) recorded a significant decrease in dentate nucleus GABA
receptors among ET patients. An inverse relationship between GABA receptor concentration and
duration of essential tremor was also noted (Paris-Robidas et al., 2012). The researchers theorize
that a reduction in GABA receptors within the dentate nucleus produces a disinhibition of deep
cerebellar pacemaker output; this propagates along the cerebello-thalamo-cortical pathways to
induce tremors (Paris-Robida et al., 2012); this is further demonstrated by a decrease of GABA
in the cerebrospinal fluid of ET cases (Mally & Baranyi, 1994; Mally, Baranyi, & Vizi, 1996).
Despite the relative uncertainty of the precise role that GABA and its receptors have in ET, it is
clear that they represent an integral component of understanding the disease process.
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Insoluble Protein Accumulation
One study noted that ET case levels of insoluble Amyloid beta in the cerebellar cortex
were substantially higher than controls (Béliveau et al., 2015). An increase in insoluble Amyloid
beta 42 was also discovered in the cerebral parietal cortex of all ET cases and the cerebellar
white matter of the majority of ET cases, a primary indication of widespread amyloidosis
(Béliveau et al., 2015). This is significant due to the central, although somewhat unclear, role of
amyloid-beta plaque accumulation in Alzheimer’s Disease cases (Bourdenx et al., 2017).
Béliveau et al., (2015) also demonstrated that high levels of Amyloid beta 42 in ET cases
correlated with excessive amounts of insoluble phosphorylated tau, unphosphorylated
Neurofilament-H (NF-H) and Leucine rich repeat and immunoglobulin domain-containing Nogo
receptor-interacting protein 1 (LINGO1), suggestive of generalized cerebellar
neurodegeneration. Elevated cerebellar LINGO1 in ET is consistent with previous research and
may be found in Parkinson’s Disease cases as well; however, it is only reported in ET duration of
greater than 20 years (Delay et al., 2014). Likewise, phosphorylated and unphosphorylated NF-H
have been demonstrated at elevated concentrations in ET cases (Louis et al., 2012). Significant
lewy body accumulation has also been recorded in the locus coeruleus of ET cases, providing
further evidence of similarities between ET and Parkinson’s Disease (Louis, 2010). It is unclear
whether the accumulation of these proteins constitutes a portion of the primary disease process or
whether they are simply biomarkers. Despite this relative uncertainty, they are regarded as an
important facet of cellular disruption in several neurodegenerative diseases and therefore these
findings are quite substantial. While more research must be performed on the prevalence and
implications of protein aggregation in the ET cerebellum and adjacent structures, the current
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literature supports the concept of ET as a primary, neurodegenerative disease process of the
cerebellum.
White and Grey Matter Deterioration
Ultrastructural white matter bundle alterations have been noted in ET (Nestrasil et al.,
2018; Pietracupa et al., 2019). Most notably, white matter abnormalities were discovered in the
corpus callosum, corticospinal tracts, superior longitudinal fasciculi, and cerebellar peduncle;
aberrations in these areas were significantly correlated with tremor severity
(Pietracupa et al., 2019; Prasad, Pandey, Saini, Ingalhalikar, & Pal, 2019). It must, however, be
noted that there is currently contradiction in the literature regarding correlations between tremor
severity and white matter alterations in ET (Nestrasil et al., 2018) and thus there is no resolution
in this matter. Grey matter damage has likewise been noted but research is inconsistent on its
distribution—isolated thalamic depreciation (Pietracupa et al., 2019) as opposed to significant
atrophy of the cerebellum (Prasad et al., 2019). Thalamic deterioration demonstrates a strong
correlation with the presence of minor cognitive impairment, a notable non-motor symptom of
ET (Pietracupa et al., 2019). Deterioration of grey matter in the thalamus and white matter of the
superior cerebellar peduncles remains consistent with the previously mentioned hypothesis of
cerebello-thalamo-cortical circuit dysfunction in ET and agrees with earlier research regarding
the integral role of this circuit in ET pathology (Hallet, 2014). However, the widespread nature
of the white matter aberrations suggests that ET pathology involves multiple brain structures, not
simply degeneration of cerebellar processes, while also supporting the concept of ET as a
neurodegenerative disorder. Research regarding widespread atrophy of the cerebellum and
cerebellar peduncles in ET provides evidence of macrostructural integrity changes and thus
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potential for future use of Magnetic Resonance Imaging as aid in diagnosis of the disease (Cao et
al., 2018; Mavroudis, Petridis, & Kazis, 2019; Prasad et al., 2019).
Much research has recently been performed regarding the heterogeneous
pathophysiology of ET. The diverse, occasionally conflicting and somewhat erratic results
provide reason to question the identity of ET as a single entity. Rather, it is quite possible that it
may in fact be a family of diseases or “the essential tremors” as put by Louis (2013). Multiple
pathological entities have been described potentiating the distinction of certain anatomical
features in ET description such as a cerebellar ET (Louis, 2009). Potential for subsets of ET have
also been noted such as the increase in non-motor symptoms associated with midline tremor in
ET (Huang et al., 2020). While this does raise concerns for future diagnosis and
research—specifically the manner in which case subjects are selected—of ET, it primarily
further exemplifies the profound need for distinctive, collaborative research.
Recent literature suggests a degenerative cascade, similar to the model referenced earlier
from Louis (2014). This putative degenerative cascade would progress from Purkinje axonal
swelling, basket cell remodeling, and the loss of GABA receptors to ultimately culminate in a
reduction of GABAergic tone (Louis & Faust, 2020). Diminution of GABAergic tone would
result in a hyperexcitable state that may produce a tremor. This theory would explain the
pathology of ET and potentiate discernment between primary degenerative aspects and
successive compensatory developments to try and restore GABAergic tone. Additional research
must be performed in order to better support this theory and provide further detail as to the
pathophysiology of ET.
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Progression
The neurodegenerative nature of ET is further supported by the progressive fashion in
which the disease presents—notably its insidious onset, gradual progression, and increased
incidence in older populations (Louis et al., 2017). There is, however, a paucity of longitudinal
research following ET patients and the severity of their symptoms; this makes it extremely
difficult to quantify the rate of progression in ET. Despite the current lack of significant
longitudinal data, several studies have demonstrated a progressive decline in ET patients over
follow-ups of 3-6 years (Gironell, Ribosa-Nogué, Gich, Marin-Lahoz, & Pascual-Sedano, 2015;
Louis, Agnew, Gillman, Gerbin & Viner, 2011; Putzke, Whaley, Baba, Wszolek, & Uitti, 2006).
Gironell et al., (2015) noted a relationship between age of disease onset and the rate of
progression; they hypothesized that the rate of progression is low when tremor symptoms are
noted prior to the age of 40 years. In contrast, Louis et al. (2017) noted a rapid rate of
progression in older-onset ET; an increased age of onset was also associated with an increase in
degenerative pathology. However, Kuo et al., (2017) noted no significant difference in cerebellar
pathology between early and late onset ET. Louis et al. (2017) further demonstrated no
significant differences in cerebellar pathology between familial and sporadic ET; this supports
the previous study due to the early nature of familial ET onset. Overall, there is much to be
learned about the progression of ET and further research is needed to clarify the relationship
between progression and other factors such as age of onset. However, it is likely that progression
rate differs considerably with varying ages of onset and thus some comfort may be provided for
patients with early onset ET.
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Etiology
Genetic Factors
There are several factors which appear to influence the likelihood of ET development.
Genetic factors play an important role as ET often presents in a familial fashion and risk of ET
development increases substantially for patients with affected family members. Louis et al.
(2001) demonstrated that the risk of developing ET is five times greater for first-degree relatives
of ET patients and ten times greater if the relative developed the tremor at an early age. Indeed,
familial tremor constitutes 50-70% of ET cases (Sullivan, Hauser, & Zesiewicz, 2004). Recent
genetic analyses have recorded 14 loci and 11 genes—notably, mutations in the LINGO1 gene
(Stefansson et al., 2009)—with some relation to ET (Deng, Wu, & Jankovic, 2019). LINGO1
gene variants in ET potentiates a connection to the increased levels of LINGO1 noted in ET
cases and suggests the need for research to determine any association between the two. Despite
recent discoveries in ET genetics, no causative genes for ET have been identified. This suggests
a complex combination of genetic factors that likely interact with the environment in the
development of ET pathology.
Environmental Factors
Diet.
Environmental factors have constituted a significant portion of the ET discussion for
quite some time, although there are varying reports regarding the nature of these factors. The
effects of diet, smoking, and occupational toxin exposure have been examined for their relation
to ET (Ong, Deng, & Tan, 2019). β-carboline alkaloids are a well-known neurotoxin and have
demonstrated tremor-inducing effects when administered to both laboratory animals and humans
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(Louis & Zheng, 2010). ET cases have demonstrated elevated levels of harmane, a β-carboline
alkaloid, as compared to healthy controls (Louis et al., 2002; Louis et al., 2008). An association
between higher harmane levels and increased severity of ET has also been reported, further
demonstrating the possible role of elevated harmane in ET (Louis et al., 2008). Harmane is found
in meat-products and is ingested in higher concentrations than it is endogenously created (Ong et
al., 2019). Despite this, ET patients have demonstrated no significant differences in animal
protein intake when compared with controls and no correlation has been found between intake
and Harmane levels (Louis, Zheng, Applegate et al., 2005). This suggests that dietary intake of
Harmane is not an adequate measure of the risk of ET development or aggravation, although
further research is necessary to make any entirely conclusive statements on the subject.
Altogether, elevated harmane levels appear to play some role in ET development and severity,
despite the unclear nature of their increase.
Historically, alcohol has been regarded as a potentially protective factor due to its
transient reduction of tremor severity upon intake (Ong et al., 2019). However, ethanol is a
well-established cerebellar toxin and may illicit degenerative effects such as Purkinje cell loss
and cerebellar atrophy, as is also noted in ET pathology (Anderson, 2004; Dlugos, 2008; Yokota
et al., 2007). Despite this degradory effect, no significant association has been found between ET
and alcohol intake (Jimenez-Jimenez et al., 2007; Louis et al., 2004). Additionally, no correlation
is noted between average alcohol intake and tremor severity, further highlighting the transient
nature of alcohol’s suppression of tremor (Louis & Michalec, 2014). Louis, Benito-Leon, and
Bermejo-Pareja (2008) did find a minor association between alcohol intake and risk of ET
development; in the study, the highest quartile of alcohol consumers—drinking an average of 3-4

ESSENTIAL TREMOR

16

standard drinks per day—demonstrated twice the risk of ET development. While this study is
rather isolated, it demonstrates a dire need for more research on the long-term effects of alcohol
on ET. Interestingly, a small Italian study recorded a negative correlation between wine
consumption and ET development, potentially due to the significant antioxidant properties of
wine (Nicoletti et al., 2011). Antioxidants have briefly been examined as a potential protective
factor. While no difference in intake of individual antioxidants such as vitamins C and E has
been found with ET patients (Louis, Jurewicz, & Parides, 2005), adherence to the Mediterannean
diet was inversely correlated with risk of ET development (Scarmeas & Louis, 2007). The
antioxidant-rich nature of the Mediterannean diet suggests a potential protective intervention that
may be made to decrease the risk of ET development. Notable aspects of the Mediterannean diet
also include decreased red meat intake and consumption of red wine in moderation, perhaps
demonstrating a broader coalition of protective interventions rather than just an increase in
overall antioxidant intake. While caffeine consumption was previously thought to increase
tremor severity, no correlation has been found between caffeine intake and the severity or
duration of ET symptoms (Nicoletti et al., 2011; Louis et al., 2004; Prakash, Choong, Yuen, &
Tan, 2006). Overall, the effects of diet on ET development and severity are not concretely
evident and further research is needed to examine the relationship between factors such as meat
intake and Harmane levels. However, current literature suggests that dietary interventions such
as a decrease in overall alcohol intake and adherence to the Mediterannean diet may decrease the
risk of ET development.
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Occupational exposure.
Several habitual and occupational hazards have also been noted as having some affect on
ET. While smoking is often regarded as a detrimental health habit, Benito-Leon, Louis, and
Bermejo-Pareja (2008) demonstrated an inverse relationship between smoking and risk of ET;
indeed, the highest pack per year group had ⅓ the risk of ET development as compared to
never-smokers. This is not entirely surprising as nicotine appears to provide some protection
from neurotoxic detriments (Picciotto & Zoli, 2008; Quick, Perez & Bordia, 2012; Shimohama,
2008). While the nicotine content received with smoking may provide some protective elements
against ET development, it is certainly not clinically recommended due to the significant health
detriments associated with chronic exposure to smoke. A positive association between pesticide
exposure and ET has also been noted (Azevedo & Meyer, 2017; Yao, Wang, & Yang, 2014).
However, other studies have demonstrated a complete lack of association between the two and
thus more research is required to further illuminate the potential effects of pesticide exposure on
the development of ET (Jimenez-Jimenez et al., 2007; Louis, Factor-Litvak, et al., 2006;
Prakash, Choong, Yuen, & Tan, 2006). ET cases have also demonstrated a higher level of blood
lead concentrations as compared to controls (Dogu et al., 2007; Louis et al., 2003). This is
significant due to the destructive nature of lead on cerebellar tissue and Purkinje cells, as is noted
in ET pathology (Ong et al., 2017).
The conflicting results of the relationship between ET and occupational exposure
provides significant difficulties in the navigation of ET risk factors. While smoking likely
decreases the risk of ET development, it is not an appropriate intervention due to its other
well-known health detriments. The role of pesticide exposure in ET is grossly unclear and further
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research is required to provide any clinical recommendations. Overall, while much research is
still required to further clarify the etiology of ET, it is likely that a complex relationship between
genes and environment exists and dictates the development of ET as multiple factors of both
parties have proven significant in their affiliation with ET.

Treatment
Although ET is not often regarded as debilitating, several treatments have been explored
and further innovations and research are providing greater potential for complex treatment
approaches to match an ever-growing knowledge of the extent and complexity of ET. Currently,
all treatments are directed at symptom reprief and do not aim to impact ET development or
progression pathologically.
Pharmacological Interventions
Historically, Propranolol and Primidone have been the primary medications prescribed in
treatment of ET symptoms (Zesiewicz et al., 2011). Propranolol and Primidone have been
demonstrated to reduce tremor for at least one year (Findley, Cleeves, Calzetti, 1985; Murray,
1976; Paparella et al., 2018; Sasso, Perucca, Fava, & Calzetti, 1990; Winkler & Young, 1974).
However, no longitudinal studies have been performed regarding the long-term efficacy of
Propranolol and Primidone. Primidone decreases tremor severity noticeably earlier than
Propranolol, but both have the same overall outcome (Dietrichson & Espen, 1987). While each
medication has independently demonstrated effective reduction in extremity tremor severity,
dual therapy provides the greatest level of tremor reduction in 30-70% of patients; however, the
overall result is rather modest (Bain, 1997; Schaefer, Rodriguez, & Louis, 2017). In addition, up
to ⅓ of patients develop pharmacoresistance (Deuschl, Raethjen, Hellriegel, & Elble, 2011) and
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discontinue their medication due to undesirable side effects and lack of satisfactory tremor
resolution (Louis, Rios, & Henchcliffe, 2010). In the event that Propranolol is contraindicated for
a patient, Metoprolol may be substituted and demonstrates similar efficacy (Calzetti, Findley,
Gresty, Perucca, & Richens, 1981; Calzetti, Findley, Perucca, & Richens, 1982). However, other
beta-blockers demonstrate inconsistent or less effective results when used to treat ET (Calzetti et
al., 1981). Topiramate may also be prescribed for moderate to severe ET, although it is less
effective than the combination therapy of Primidone and Propranolol (Connor & Edwards, 2008;
Ferreira et al., 2019; Ondo et al., 2006; Schaefer, Rodriguez, & Louis, 2017). Some research has
demonstrated a possible use for botulinum neurotoxin injection in reduction of tremor severity
(Ferreira et al., 2019). While other medication regimes target extremity tremors of the disease,
use of botulinum toxin type A has exhibited significant improvement in head and voice tremor
(Adler et al., 2004; Gurey, Sinclair, & Blitzer, 2013; Guglielmino, Moraes, Villanova, Padovani,
& Biase, 2018; Hertegård, Granqvist, & Lindestad, 2000; Pahwa et al., 1995; Warrick et al.,
2009; Wissel, Masuhr, Schelosky, Ebersbach, & Poewe, 2004). Nonetheless, additional research
is required to ensure the appropriateness of botulinum administration for ET. Pharmacological
interventions appear to primarily provide transient relief and other interventions must be sought
out for long-term treatment of ET symptoms.
Surgical Interventions
Several other treatment methods for ET exist, one of which is Deep Brain Stimulation
(DBS) of the ventralis intermedius nucleus of the thalamus. DBS has proven effective for at least
one year post-operation (Borretzen et al., 2014; Koller et al., 1997; Koller, Lyons, Wilkinson,
Troster, & Pahwa, 2001; Pahwa et al., 2001). However, Borretzen et al. (2014) noted that up to
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40% of patients develop a tolerance and thus efficacy of DBS significantly decreases over time.
Additional studies displayed a 73% reduction in long-term efficacy of DBS (Wang et al., 2018;
Sandoe et al., 2013). Despite the unfortunate decrease in desirable outcome duration, DBS
demonstrates up to a 90% reduction in tremor severity and consequently an increase in overall
functionality (Nazzarro, Lyons, & Pahwa, 2013). Bilateral DBS has been noted to be more
effective than a unilateral approach (Pahwa et al., 2006). Unfortunately, bilateral procedures are
associated with an increase in adverse side effects, such as gait disturbances and dysarthria, when
compared to unilateral DBS (Nazzarro, Lyons, & Pahwa, 2013).
A thalamotomy may also be performed to reduce severe tremors in ET. A similar efficacy
has been demonstrated between unilateral DBS and thalamotomy—up to 90% effective in
suppression of limb tremor (Giordano et al., 2020; Jankovic, Cardoso, Grossman, & Hamilton,
1995; Kim et al., 2017; Tasker et al., 1997; Park, Jung, Na, & Chang, 2019; Witjas et al., 2015;
Zirh, Reich, Dougherty, & Lenz, 1999). However, bilateral DBS shows the greatest improvement
of tremor severity overall (Giordano et al., 2020). There is minor evidence that non-invasive
brain stimulation, primarily of the cerebellar and motor cortical regions, has a positive affect on
tremor severity (Chalah, Lefaucheur, & Ayache, 2015; Kang & Cauraugh, 2017). However,
further research is needed to confirm the veracity of these results. Altogether, surgical
interventions for ET appear to provide the greatest relief of symptoms, but they mimic the
pharmacological interventions in the transiency of their effects.
Alternative Interventions
Several innovative studies have sought to measure the potential of supportive
exoskeletons or “orthoses'' for non-pharmacological treatment of ET. Multiple studies have
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demonstrated a significant reduction in tremor amplitude and occurrence with the application of
orthoses (Herrnstadt, McKeown, & Menon, 2016; Herrnstadt & Menon, 2019; Loureiro et al.,
2005). One study even demonstrated a 98% reduction in tremor with use of the orthosis (Rocon
et al., 2007). Despite these impressive results, the devices were not tolerated well and patients
complained of the bulky nature of the instruments (Castrillo-Fraile et al., 2019). A multichannel
stimulator utilizing asynchronous electrode activation has also been developed and demonstrates
a decrease in tremor amplitude of up to 80% (Maneski et al., 2011).
Alternative medicine therapies have also been briefly explored. Kang et al. (2020)
recorded that 70% of ET patients who used Korean herbal medicine reported that it was highly
effective at treating their tremor symptoms. While this demonstrates some potential for herbal
treatment, it is difficult to assess the true validity of these results as the data was self-reported by
patients. While orthoses and other innovations seem to provide substantial relief in ET symptom
severity, they do not appear to be feasible for everyday use due to their cumbersome nature.
Overall, it is clear that extensive research must be performed in order to better develop and
evaluate treatment options for ET.

Conclusion
Despite considerable research efforts over recent years, ET remains relatively unclear in
its pathophysiology, inconsistent in its presentation, and considerably uncertain in its etiology.
Treatment methods show promising results, but they rapidly decrease therapeutically or are
impractical for everyday activities. Significant research must continue so as to refine current
theories, distinguish the cause of symptom anomalies, enrich our etiological knowledge, and
provide additional therapies for patients. Although much is still unknown, the substantial
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advance in ET literature over the past 15 years is encouraging and provides hope for rapid
accumulation of disease knowledge in the future.
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